Toutes les études
RecrutementConfirmatoire thérapeutique (Phase III)Interventionnel

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

ENPP1 deficiency is a very rare genetic condition where the body cannot make enough of an essential enzyme. This leads to low levels of a substance called pyrophosphate, causing problems with bone strength, rickets, and calcium build-up in blood vessels. The ENERGY 3 trial is a Phase 3 study looking at a new treatment called INZ-701 in children with this condition. The main aim is to find out if INZ-701 can restore healthy mineral levels in the blood and help heal bone problems caused by rickets. Doctors will measure bone changes using X-rays and track each child's height, weight, and general health over 52 weeks. Taking part helps researchers understand if this treatment is safe and effective for long-term use.

En un coup d'œil

Statut
Recrutement
Phase
Confirmatoire thérapeutique (Phase III)
Sponsor
Inozyme Pharma Inc.
Objectif d'inscription
8
Démarrer
06 Mar 2024

De quoi parle cette étude ?

ENPP1 deficiency is a rare inherited condition that affects how the body manages minerals like calcium and phosphate. In healthy bodies, an enzyme called ENPP1 produces a protective substance called pyrophosphate, which stops calcium from building up where it should not, while keeping bones strong. Children with this condition often experience weakened bones, rickets, and problems in their blood vessels.

INZ-701 is an experimental medicine designed to act as an enzyme replacement. By providing the missing enzyme activity, it aims to boost levels of pyrophosphate in the blood. If successful, this could help prevent abnormal calcium deposits, support normal bone development, and relieve symptoms related to bone weakness.

The ENERGY 3 study is a Phase 3 clinical trial, which means it is an advanced stage of testing. Researchers want to confirm how well INZ-701 works and check its safety in children. Over 52 weeks (one year), the study team will closely monitor whether the medicine improves rickets on X-rays, aids normal physical growth, and keeps children safe from unwanted side effects.

Points clés

  • ENERGY 3 is testing INZ-701, an experimental medicine for children with ENPP1 deficiency.
  • The treatment aims to restore healthy mineral levels and heal bone problems like rickets.
  • Children will be monitored closely for 52 weeks with blood tests, X-rays, and growth checks.
  • Participation is entirely voluntary, and families can withdraw at any point.

Qui peut être éligible ?

This trial is specifically for children who have been diagnosed with ENPP1 deficiency. It is open to both boys and girls. Because this is a specialist study for a rare condition, a doctor will need to confirm the diagnosis through genetic testing and clinical checks.

Children will need to be well enough to attend regular hospital check-ups and complete tests such as blood draws and imaging scans.

Not every child with the condition will be able to join. Factors such as other serious medical conditions, recent use of certain medications, or specific allergies may mean a child cannot safely take part. The study doctor can review these details with families.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. My child has a confirmed diagnosis of ENPP1 deficiency.
  2. My child is a child or young person suitable for paediatric study monitoring.
  3. We are able to attend regular hospital appointments over a 52-week period.
  4. We are willing for our child to have regular blood tests, growth checks, and bone X-rays.
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

Taking part in the ENERGY 3 study lasts for around 52 weeks (one year). During this time, children will receive the study medicine, INZ-701, and attend regular appointments at a specialist hospital clinic. At these visits, the medical team will carry out physical examinations, check vital signs, and measure height and weight to track growth. Children will have regular blood tests to check levels of pyrophosphate and monitor how the medicine is working in the body. The team will also take X-rays to assess bone healing and look for any signs of rickets. Parents and carers will be supported by the study team throughout, with regular follow-up checks to monitor health and wellbeing.

Risques et avantages potentiels

Joining the study may offer the potential benefit of improving your child's bone health, mineral balance, and physical growth, although benefits cannot be guaranteed. There are also risks to consider. As with any new medicine, INZ-701 may cause unexpected side effects or reactions around the injection site, and study tests like blood samples can cause mild discomfort. Taking part is completely voluntary. You are free to withdraw your child from the study at any time without giving a reason, and this will never affect their standard NHS care.

Emplacements (2)

Certains emplacements de site sont approximatifs. Nous améliorons cela — veuillez vérifier avec l'équipe d'essai avant de vous déplacer.
  • —
    Non vérifié
    France
  • —
    Non vérifié
    Espagne

Questions fréquentes

What is ENPP1 deficiency?

It is a rare genetic condition where the body lacks an important enzyme, leading to weak bones, rickets, and calcium deposits in tissues.

What is the purpose of the ENERGY 3 study?

The study aims to find out if the medicine INZ-701 is safe and effective at balancing minerals and improving bone growth in children.

Combien de temps dure l'étude ?

The main part of the study runs for 52 weeks (approximately one year) of treatment and regular monitoring.

Will taking part cost anything?

No, the study medicine and all related tests are provided free of charge. Travel expenses to study visits are usually reimbursed.

Can my child leave the study if we change our mind?

Yes, you can choose to stop participating at any time. Your child's normal medical care will continue as usual.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Ph… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.